Health
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum mana
About this update from Fulcrum Therapeutics, Inc.
[{"type":"image","alt":"Fulcrum Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Fulcrum Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/b2436aacd8d6614fd2b1c157e4f5cc27"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n.X.8ZqQNvv9C0Ig4vezOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b2436aacd8d6614fd2b1c157e4f5cc27","width":300,"height":73}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.","length":476,"tagName":"p"},{"type":"text","content":"Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine.","length":203,"tagName":"p"},{"type":"text","content":"To register for this event, please click here or visit the “Events and Presentations” section of Fulcrum’s website. A replay will be available on Fulcrum’s website following the event.","length":184,"tagName":"p"},{"type":"text","content":"About Martin H Steinberg, MDDr. Martin H Steinberg, MD is a hematologist with a clinical and research focus on disorders of the red blood cell with special emphasis on sickle cell disease. He has published more than 450 articles and 3 textbooks on the science and clinical features of sickle cell disease and related disorders. A graduate of Cornell University and Tufts University School of Medicine he completed post-graduate training in New York and Boston. He has participated in basic, translational, and clinical studies devoted to understanding the pathophysiology and genetic basis of phenotypic heterogeneity in sickle cell disease. Using candidate gene, genome-wide association studies, next-generation sequencing, and induced pluripotent stem cells to understand the genetic determinant...